Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.77 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.77 |
| ▸ | TNKS | O95271 | 1/20 | 0.73 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30888475 | 1.00 | PARP1 (1.00) | PARP1PARP2PARP3TNKSTNKS2 | |
| SCHEMBL19005724 | 0.94 | PARP1 (0.88) | PARP1PARP2PARP3TNKSTNKS2 | |
| SCHEMBL30888477 | 0.94 | PARP1 (0.88) | PARP1PARP2PARP3TNKSTNKS2 | |
| SCHEMBL19005624 | 0.94 | PARP1 (0.88) | PARP1PARP2PARP3TNKSTNKS2 | |
| SCHEMBL19005242 | 0.92 | PARP1 (0.85) | PARP1PARP3TNKSTNKS2 | |
| SCHEMBL19005258 | 0.92 | PARP1 (0.84) | PARP1PARP3TNKSTNKS2 | |
| SCHEMBL30546224 | 0.91 | PARP1 (0.84) | PARP1PARP2PARP3TNKSTNKS2 | |
| SCHEMBL26122828 | 0.91 | PARP1 (0.84) | PARP1PARP2PARP3TNKSTNKS2 | |
| SCHEMBL10025694 | 0.89 | PARP1 (0.80) | PARP1PARP3TNKSTNKS2 | |
| SCHEMBL19005693 | 0.89 | PARP1 (0.79) | PARP1PARP3TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023288002-A1 | PHTHALAZINONE-BASED PARP-1 INHIBITORS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-01-19 | — | — | WO | disclosed |
| US-9566277-B2 | Methods of using phthalazinone ketone derivatives | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2017-02-14 | — | — | US | disclosed |
| US-9566277-B2 | Methods of using phthalazinone ketone derivatives | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2017-02-14 | — | — | US | disclosed |
| US-9566277-B2 | Methods of using phthalazinone ketone derivatives | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2017-02-14 | — | — | US | disclosed |
| US-20160151367-A1 | METHODS OF USING PHTHALAZINONE KETONE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-02 | — | — | US | disclosed |
| US-20160151367-A1 | METHODS OF USING PHTHALAZINONE KETONE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-02 | — | — | US | disclosed |
| US-20160151367-A1 | METHODS OF USING PHTHALAZINONE KETONE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-02 | — | — | US | disclosed |
| EP-2604610-B1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL (CN) | 2016-05-11 | — | — | EP | disclosed |
| US-9273052-B2 | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2016-03-01 | — | — | US | disclosed |
| US-9273052-B2 | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2016-03-01 | — | — | US | disclosed |
| US-9273052-B2 | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2016-03-01 | — | — | US | disclosed |
| US-20150166544-A1 | PIPERAZINOTRIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION | SHANGHAI ACEBRIGHT PHARMACEUTICALS CO., LTD. (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166544-A1 | PIPERAZINOTRIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION | SHANGHAI ACEBRIGHT PHARMACEUTICALS CO., LTD. (CN) | 2015-06-18 | — | — | US | disclosed |
| EP-2604610-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | Jiangsu Hansoh Pharmaceutical Co., Ltd. (CN) | 2013-06-19 | — | — | EP | disclosed |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| WO-2012019427-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166544-A1 | PIPERAZINOTRIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION | PARP1, PARP11, PARP8 | PARP1 1/4885PARP2 7/4885PARP3 4/4885 |
| US-20160151367-A1 | METHODS OF USING PHTHALAZINONE KETONE DERIVATIVES | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885PARP3 3/4885 |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | PARP1, PARP2, PARP4 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.